{"id":7852,"date":"2026-05-19T15:00:00","date_gmt":"2026-05-19T13:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c5f97413e70d182917e847afd4d2c612"},"modified":"2026-05-19T15:00:00","modified_gmt":"2026-05-19T13:00:00","slug":"hitlab-validates-medsengines-value-in-treating-chronic-diseases","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7852","title":{"rendered":"\u00a0HITLAB Validates MedsEngine\u2019s Value in Treating Chronic Diseases"},"content":{"rendered":"

NEW YORK--(BUSINESS WIRE)--HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine<\/b><\/a>\u00ae<\/sup>. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis using the Nielsen heuristic framework, comprehensive review of the peer-reviewed evidence, and economic value analysis.<\/p><\/a><\/a>

\nHITLAB Chairman, Stan Kachnowski stated, \u201cMedsEngine is among the most clinically rigorous and outcomes-validated decision support platforms HITLAB has evaluated. In a landscape crowded with digital health promises, MedsEngine delivers something rare: a decade of real-world evidence that durably moves the needle on chronic disease control at scale.\u201d<\/i><\/p>

\nThe four disease modules that MedsEngine supports impact over 60% of the adult population and represent nearly 64% of chronic disease cost. Dr. Doug Romer, MedsEngine CMO, stated, \u201cHITLAB\u2019s findings identify the improved outcomes and cost benefits derived from using MedsEngine to treat chronic diseases. Users achieved US leading hypertension control for over 90% of patients in less than 2 office visits. Clinicians can provide guideline directed treatment for type 2 diabetes and cholesterol management in a matter of seconds.\u201d<\/i><\/p>

\nMedsEngine uses secure FHIR-based interoperability with EHR\u2019s to turn patient-specific data already available in the EHR into guideline-directed recommendations within the clinician\u2019s workflow, reducing manual review and improving office efficiency.<\/p>

\nFor more information about MedsEngine or to view the full HITLAB report visit www.medsengine.com<\/a> or contact us at hello@medsengine.com<\/a><\/p>

\nAbout MedsEngine<\/b><\/p>

\nMedsEngine develops EHR-integrated clinical decision support applications that generate real-time, personalized, evidence-based medication recommendations for hypertension, cholesterol management, type 2 diabetes, and heart failure<\/b>. Medical groups utilizing MedsEngine have seen nation-leading hypertension control, higher HEDIS scores and Star ratings, lower medical costs, standardized care across all providers, improved office workflow and greater patient understanding and satisfaction.<\/p> Contacts<\/b>

\nhello@medsengine.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine\u00ae. HITLAB was engaged to conduct an independent, structured …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7852","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7852"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7852\/revisions"}],"predecessor-version":[{"id":7853,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7852\/revisions\/7853"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}